Education
About Us
Working with TipRanks
Follow Us
Inhibrx Biosciences, Inc. (INBX)
:INBX
INBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.80 - $25.29
Previous CloseN/A
Volume23.61K
Average Volume (3M)129.01K
Market Cap
$312.68M
Enterprise Value$106.41M
Total Cash (Recent Filing)$216.52M
Total Debt (Recent Filing)$106.53M
Price to Earnings (P/E)0.2
Beta0.53
Next Earnings
Aug 19, 2025EPS Estimate
-2.76Last Dividend Ex-Date
May 30, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-2.80
Shares Outstanding14,475,904
10 Day Avg. Volume109,217
30 Day Avg. Volume129,008
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue532.04
Enterprise Value/Gross Profit-110.38
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$15.00Price Target Upside-31.19% Downside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Drug EfficacyOzekibart FOLFIRI combo shows 40% ORR, demonstrating effectiveness in heavily pretreated CRC patients.
Financial CapabilityInhibrx is well capitalized with $196.3 million in cash, allowing continued development of its key treatments.
Progression-Free SurvivalThe 7.85-month median PFS shows promising results when compared to expected outcomes for 2L+ CRC.
Bears Say
Adverse Effects31% of patients experienced an increase in alanine aminotransferase, indicating potential safety issues.
Safety ConcernsA patient passed away due to neutropenic sepsis, raising concerns about the safety profile of the treatment.
Safety Profile LimitationsThe safety profile of the combination therapy may limit its use, especially given the grade 5 event possibly linked to FOLFIRI.
Inhibrx Biosciences Inc News
INBX FAQ
What was Inhibrx Biosciences, Inc.’s price range in the past 12 months?
Inhibrx Biosciences, Inc. lowest stock price was $10.80 and its highest was $25.29 in the past 12 months.
What is Inhibrx Biosciences, Inc.’s market cap?
Inhibrx Biosciences, Inc.’s market cap is $312.68M.
When is Inhibrx Biosciences, Inc.’s upcoming earnings report date?
Inhibrx Biosciences, Inc.’s upcoming earnings report date is Aug 19, 2025 which is in 12 days.
How were Inhibrx Biosciences, Inc.’s earnings last quarter?
Currently, no data Available
Is Inhibrx Biosciences, Inc. overvalued?
According to Wall Street analysts Inhibrx Biosciences, Inc.’s price is currently Overvalued.
Does Inhibrx Biosciences, Inc. pay dividends?
Inhibrx Biosciences, Inc. pays a Notavailable dividend of $0.85 which represents an annual dividend yield of N/A. See more information on Inhibrx Biosciences, Inc. dividends here
What is Inhibrx Biosciences, Inc.’s EPS estimate?
Inhibrx Biosciences, Inc.’s EPS estimate is -2.76.
How many shares outstanding does Inhibrx Biosciences, Inc. have?
Inhibrx Biosciences, Inc. has 14,475,904 shares outstanding.
What happened to Inhibrx Biosciences, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inhibrx Biosciences, Inc.?
Currently, no hedge funds are holding shares in INBX
Inhibrx Biosciences Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.00 (-31.19% Downside)
$15.00 (-31.19% Downside)
Hedge Fund Trend
Increased
By 358.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.19%
12-Months-Change
Fundamentals
Return on Equity
3250.55%
Trailing 12-Months
Asset Growth
-15.92%
Trailing 12-Months
Company Description
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences Inc (INBX) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
INBX Stock 12 Month Forecast
Average Price Target
$15.00
▼(-31.19% Downside)
Technical Analysis
Prothena
―
CytomX Therapeutics
―
Humacyte
―
Monte Rosa Therapeutics
―
Candel Therapeutics
―
Ownership Overview
15.47% Insiders
6.53% Mutual Funds
47.08% Other Institutional Investors
23.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---